PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 8425021

Nucleoside analogs: similarities and differences.

J P Sommadossi
View original source ↗Export metadata ↓

Abstract

Among the steps in the replication cycle of human immunodeficiency virus (HIV) that are potential targets for antiviral chemotherapy, the viral DNA polymerase or reverse transcriptase has been a target of choice in research on anti-HIV drugs. Nucleoside analogs--the agents studied in relation to this target--have no intrinsic activity against HIV and must be metabolized to their respective 5'-triphosphates by means of kinases, nucleotidases, or other activating enzymes present naturally in cells. The presence and activity of the intracellular enzymes necessary for activation of nucleoside analogs are highly dependent on host species, cell type, and stage in the cell cycle. A great advantage of 2',3'-dideoxynucleosides is their intracellular pharmacokinetic profile. The multifactorial mechanisms of toxicity associated with this class of drugs likely explain the different spectra of toxicity observed with the various individual nucleoside analogs and exemplify the uniqueness of each compound. Recently, strains of HIV resistant to 3'-azido-3'-deoxythymidine (zidovudine) were isolated from patients who had been treated with this drug; this resistance probably reflects sequential acquisition of amino acid mutations in the HIV reverse transcriptase.

Explore related subjects

DNA-Directed DNA PolymeraseDideoxynucleosidesGene ExpressionHIVHumansJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, P.H.S.Review

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J P Sommadossi. 1993. Nucleoside analogs: similarities and differences.. https://doi.org/10.1093/clinids%2F16.supplement_1.s7

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1997

Elimination of background signals in a modified polymerase chain reaction-based reverse transcriptase assay.

Three highly sensitive reverse transcriptase (RT) assays were recently published that are at least one million times more sensitive than conventional RT assays. These assays derive their high sensitivities through the ability to amplify the complementary DNA (cDNA) product of the RT reaction by the polymerase chain reaction (PCR). We describe a modified PCR-based RT (PBRT) assay that retains the high sensitivities of the original assays while reducing their inherent background signals. The background signal of the PBRT assay was found to be due to an intrinsic RNA-dependent DNA polymerase activity of the Taq DNA polymerase, the enzyme used for the PCR. It could be eliminated by inserting a ribonuclease digestion step prior to amplifying the cDNA product of the RT reaction by PCR and by using a thermostable DNA polymerase identified as having reduced RNA-dependent DNA polymerase activity. Comparable results were obtained using three RNA templates with two purified RT enzymes. This modified assay is capable of detecting reliably between 10 and 100 molecules of RT, which is equivalent to between 1 and 10 retrovirus particles.

DNA-Directed DNA Polymerase↗
PubMed1997

Hepatitis B virus replication and mutation are autoregulated by interactions between surface antigen and HBeAg and the HBV DNA polymerase: a functional model with therapeutic implications.

Infection with hepatitis B virus can result in asymptomatic seroconversion with viral clearance, fulminant hepatic failure and death, or chronic, typically lifelong, transmissible infection. The mechanism(s) of viral persistence are poorly understood but viral clearance and fulminant hepatic failure are generally thought to result from co-ordinated and effective and abnormally vigorous immune responses, respectively, whereas viral persistence results from immunological failure in addition to poorly characterized viral factors promoting persistence. This paper proposes (1) that the predominant viral factor(s) promoting persistence of hepatitis B virus are homeostatic mechanism(s) responsible for modulating its replication and mutation and (2) that chronic hepatitis B results when these mechanisms are successful and other outcomes occur when these homeostatic mechanism(s) fail. Furthermore, it is proposed that seroconversion (e.g. from HBsAg to anti HBsAg positivity), when it occurs, is a consequence facilitated by restricted viral antigenic diversity and reduced viral replication rather than a proximate cause of it. The specific homeostatic mechanisms proposed--negative feedback inhibition of hepatitis B virus DNA polymerase/reverse transcriptase mediated by HBs antigen and a hepatitis B virus DNA polymerase fidelity modulating function of HBeAg--are consistent with the available data and resolve many paradoxical clinical observations. But, more importantly, this model has clear implications for therapy, including the rational design of drugs and therapeutic vaccines.

DNA-Directed DNA Polymerase↗